Interventions for unexplained subfertility : A systematic review and network meta-analysis by Tjon-Kon-Fat, Raissa I. et al.
Cochrane Database of Systematic Reviews
Interventions for unexplained subfertility: a systematic
review and network meta-analysis (Protocol)
Tjon-Kon-Fat RI, Wang R, Eijkemans MJC, Bossuyt PMM, Mol BWJ, Van der Veen F, Bhattacharya
S, van Wely M
Tjon-Kon-Fat RI, Wang R, Eijkemans MJC, Bossuyt PMM, Mol BWJ, Van der Veen F, Bhattacharya S, van Wely M.
Interventions for unexplained subfertility: a systematic review and networkmeta-analysis.
Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No.: CD012692.
DOI: 10.1002/14651858.CD012692.
www.cochranelibrary.com
Interventions for unexplained subfertility: a systematic review and networkmeta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions for unexplained subfertility: a systematic review and network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Interventions for unexplained subfertility: a systematic review
and network meta-analysis
Raissa I Tjon-Kon-Fat1 , RuiWang2 , Marinus JC Eijkemans3, PatrickMMBossuyt4 , BenWillem JMol2, Fulco Van der Veen1, Siladitya
Bhattacharya5, Madelon van Wely1
1Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 2Discipline of
Obstetrics and Gynaecology, School of Medicine, Robinson Research Institute, The University of Adelaide, Adelaide, Australia.
3Department of Biostatistics and Research Support, Julius Center, UMC Utrecht, Utrecht, Netherlands. 4Department of Clinical Epi-
demiology, Biostatistics and Bioinformatics, AcademicMedical Center,University of Amsterdam, Amsterdam,Netherlands. 5Obstetrics
and Gynaecology, Aberdeen Maternity Hospital, Aberdeen, UK
Contact address: Madelon van Wely, Center for Reproductive Medicine, Academic Medical Center, University of Amsterdam,
Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands. m.vanwely@amc.uva.nl.
Editorial group: Cochrane Gynaecology and Fertility Group.
Publication status and date: New, published in Issue 6, 2017.
Citation: Tjon-Kon-Fat RI, Wang R, Eijkemans MJC, Bossuyt PMM, Mol BWJ, Van der Veen F, Bhattacharya S, van Wely M.
Interventions for unexplained subfertility: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews
2017, Issue 6. Art. No.: CD012692. DOI: 10.1002/14651858.CD012692.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
We aim to assess the comparative effectiveness and/or safety of interventions currently being used to treat couples with unexplained
subfertility.
B A C K G R O U N D
Description of the condition
Up to 1 in 10 couples who try to achieve a pregnancy, fail to
do so after 12 months of unprotected intercourse (Boivin 2007;
Gnoth 2003). These couples will undergo routine fertility investi-
gations comprising an assessment of ovulation, tubal patency and
semen analysis. Of these couples, approximately a quarter will be
diagnosed with unexplained subfertility, when no abnormality is
found after these investigations (Brandes 2010; Hull 1985). Most
of these couples still have a good chance of achieving a pregnancy
without treatment (Brandes 2011).
Description of the intervention
Clinical guidelines for the management of unexplained subfertil-
ity recommend starting with the least invasive intervention before
moving on to more aggressive treatments (ASRM 2006; NICE
2013; NVOG 2010). In clinical practice this has led to a wide
range of interventions that are used: expectant management (i.e.
sexual intercourse), timed intercourse, ovarian stimulation (i.e. go-
nadotropins, aromatase-inhibitors or anti-estrogens), intrauterine
insemination (IUI) with or without ovarian stimulation, in vitro
fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).
Expectant management or timed intercourse
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Couples following ’expectant management’ still have a good
chance of achieving a pregnancy without treatment. A cumula-
tive ongoing pregnancy rate of 27% has been reported after 12
months of unprotected intercourse following the completion of
the fertility investigations in a large prospective cohort (Hunault
2005; van Eekelen 2017).
IUI
Delivery rates of approximately 8% per cycle have been reported
for subfertile couples with varying causes of subfertility (Kupka
2016).
IVF and ICSI
Clinical pregnancy rates of 29% per cycle have been reported af-
ter IVF and 28% per cycle after ICSI for subfertile couples with
varying causes of subfertility (Kupka 2016).
How the intervention might work
In couples with unexplained subfertility, a biological cause for their
involuntary childlessness has not been detected. For each possible
treatment for these couples there are hypotheses regarding their
working mechanisms.
The concept behind timed intercourse is to aid couples in having
intercourse at the best time for fertilisation through the use of cycle
monitoring. Ovarian stimulation is used to stimulate follicular
growth to increase the number of mature oocytes available for
fertilisation. IUI brings the spermatozoa closer to the oocyte for
fertilisation at the appropriate time.
IVF bypasses several steps in the process of conception, such as
cervical factors and problems with transport of spermatozoa. ICSI
could overcome subtle abnormalities of the sperm that hinder the
sperm-oocyte interaction.
Why it is important to do this review
There are various reviews of interventions for couples with unex-
plained subfertility (Athaullah 2002; Gunn 2016; Hughes 2010;
Pandian 2015; Veltman-Verhulst 2016). These reviews have in-
cluded head to head comparisons of two interventions at the same
time, yet as there is a wide range of available treatments, they ul-
timately do not answer the question which one of the many in-
terventions is the most effective and safe. Network meta-analysis
could provide away of identifying themost effective and safe inter-
vention by not only incorporating head to head direct comparisons
but also by using indirect comparison techniques for treatments
that have not been directly assessed in randomised controlled tri-
als. The network meta-analysis could also be used to identify gaps
in research.
O B J E C T I V E S
We aim to assess the comparative effectiveness and/or safety of in-
terventions currently being used to treat couples with unexplained
subfertility.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing the comparative effec-
tiveness and/or safety of one of the interventions compared to the
other intervention. We will exclude quasi-randomised and non-
randomised studies. Cross-over trials will be included, but only
data from the first phase will be used.
Types of participants
Couples who have been trying to conceive for at least one year,
the woman having at least one patent fallopian tube, an ovulatory
cycle and no or mild endometriosis (American Fertility Society
(AFS) criteria I) and the man having a prewash total motile sperm
count > 3 * 106.
Types of interventions
We will consider all trials where one of these interventions is com-
pared.
• Expectant management.
• Timed intercourse.
• Ovarian stimulation using gonadotropins, aromatase-
inhibitors or anti-estrogens.
• Intrauterine insemination (IUI) without ovarian
stimulation.
• IUI with ovarian stimulation.
• In vitro fertilisation (IVF) with either a single embryo
transfer, dual embryos transferred, in a modified natural cycle or
combined with intracytoplasmic injection (ICSI).
The interventions of expectant management and timed inter-
course will be combined, if no invasive techniques are used.
The reported interventions will be compared to each other or to
no intervention (i.e. expectant management).
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Types of outcome measures
Primary outcomes
1. The primary effectiveness outcome is a composite of cumulative
live birth (live birth is defined as the birth of a living child after 24
weeks of gestation) or ongoing pregnancy (defined as a registered
embryonic heartbeat on ultrasound at 12 weeks of gestation); cu-
mulative refers to multiple attempts to conceive, i.e. multiple cy-
cles or fresh IVF followed by cryo cycles).
2. The primary safety outcome is multiple pregnancy (defined as
two registered embryonic heartbeats on ultrasound).
Secondary outcomes
Secondary outcomes are:
3. clinical pregnancy (defined as a registered embryonic heartbeat
on ultrasound); and
4.moderate/severe ovarian hyperstimulation syndrome (defined as
increased abdominal discomfort with symptoms of nausea, vom-
iting or diarrhoea, the presence of ascites on ultrasound, and an
ovarian size of at least 8 cm).
Search methods for identification of studies
Wewill search for all published and unpublished randomised con-
trolled trials (RCTs), without language or date restriction, in con-
sultation with the Cochrane Gynaecology and Fertility Group
(CGF) Information Specialist.
Electronic searches
We will search the following electronic databases for relevant trials
from inception onwards.
• The Cochrane Gynaecology and Fertility Group (CGF)
specialised register of controlled trials (Procite platform)
(Appendix 1).
• The Cochrane Central Register of Studies Online (CRSO
Web platform) (Appendix 2).
• MEDLINE (Ovid platform) (Appendix 3).
• Embase (Ovid platform) (Appendix 4).
• PsycINFO (Ovid platform) (Appendix 5).
• CINAHL (Ebsco platform) (Appendix 6).
The MEDLINE search will be combined with the Cochrane
highly sensitive search strategy for identifying randomized trials,
which appears in the Cochrane Handbook for Systematic Reviews
of Interventions (Version 5.1.0, chapter 6, 6.4.11). The Embase,
PsycINFO and CINAHL searches will be combined with trial fil-
ters developed by the Scottish Intercollegiate Guidelines Network
(www.sign.ac.uk/methodology/filters.html#random).
Other electronic sources of trials will include:
• trial registers for ongoing and registered trials:
◦ www.clinicaltrials.gov (a service of the US National
Institutes of Health);
◦ www.who.int/trialsearch/Default.aspx (The World
Health Organisation International Trials Registry Platform
search portal);
• the Virtual Health Library Regional Portal (VHL) (
bvsalud.org/portal/?lang=en) which includes LILACS; and
• PubMed and Google Scholar (for recent trials not yet
indexed in the major databases).
Searching other resources
We will handsearch reference lists of relevant trials and systematic
reviews retrieved by the search and contact experts in the field to
obtain additional data. We will also handsearch relevant journals
and conference abstracts that are not covered in theCGFG register,
in liaison with the Information Specialist.
Data collection and analysis
Selection of studies
Two investigators (RT and RW) will independently assess trial
eligibility, according to the Criteria for considering studies for this
review. We will resolve disagreements through discussion with a
third investigator (MW). A PRISMA flow diagram will be drawn
to show the results of the search and the number of included and
excluded trials. The reasons for excluding any potentially-eligible
studies identified by the search from the (network) meta-analysis
will be documented.
Data extraction and management
For all included trials two authors (RT and RW) will indepen-
dently extract data using a data abstraction form and summarise
trial characteristics in tables. From each included study we will
extract baseline characteristics of the couples (i.e. female age, du-
ration of subfertility, body mass index, prior treatment), study
settings, methods, the types of interventions (used dose, type
of preparation, regimens, co-interventions) and the outcomes.
Where studies have multiple publications the authors will collate
multiple reports of the same study under a single study identifier
with multiple references. We will correspond with study investi-
gators for further data on methods and results, as required.
Assessment of risk of bias in included studies
Two authors (RT and RW) will independently assess the risk of
bias for each eligible study by using the Cochrane ’Risk of bias’
3Interventions for unexplained subfertility: a systematic review and network meta-analysis (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
assessment tool (Higgins 2011) which includes six domains: selec-
tion (random sequence generation and allocation concealment);
performance (blinding of participants and personnel); detection
(blinding of outcome assessors); attrition (incomplete outcome
data); reporting (selective reporting); and other bias. Disagree-
ments will be resolved by discussion with a third investigator
(MW). We will describe all judgements fully and present the con-
clusions in the ’Risk of bias’ table, which will be incorporated into
the interpretations of review findings by means of sensitivity anal-
yses. With respect to within-trial selective reporting, where identi-
fied studies fail to report the primary outcome of live birth, but do
report interim outcomes such as pregnancy, we will assess whether
the interim values are similar to those reported in studies that also
report live birth.
Measures of treatment effect
For dichotomous data (e.g. live birth rates), we will use the num-
bers of events in the control and intervention groups of each study
to calculate Mantel-Haenszel odds ratios (ORs). We will present
95% confidence intervals for all outcomes. Where data to calcu-
late ORs are not available, we will utilise the most detailed nu-
merical data available that may facilitate similar analyses of in-
cluded studies (e.g. test statistics, P values). We will assess whether
the estimates calculated in the review for individual studies are
compatible in each case with the estimates reported in the study
publications. When more than two studies compared the same
treatments, a random-effects pooled OR will be calculated. The
random-effects model incorporates the between study variability
and is more conservative than the fixed-effect model.
For each pairwise comparison we will present a 95% predictive
interval; this can be interpreted as the 95% interval of the expected
treatment effect in a new trial with this comparison (Salanti 2011).
Furthermore we will calculate the probability that an intervention
is ranked first, second and so on. We will display this ranking
graphically for the primary and secondary outcomes using the sur-
face under the cumulative ranking (SUCRA), where the SUCRA
values can range from zero (i.e. the intervention is certain to be
the worst) to one (i.e. the intervention is certain to be the best).
Unit of analysis issues
The primary analysis will be cumulative rates of each outcome per
woman randomised. Data that do not allow valid analysis (e.g.
’per cycle’ data) will be briefly summarised in an additional table
and will not be meta-analysed. Multiple births will be counted as
one live birth event. Only first-phase data from cross-over trials
will be included.
Dealing with missing data
We will analyse the data on an intention-to-treat basis as far as
possible (i.e. including all randomised participants in the analy-
sis, in the groups to which they were randomised). Attempts will
be made to obtain missing data from the original trialists. Where
data are unobtainable, we will undertake imputation of individual
values only for the primary outcome of live birth or ongoing preg-
nancy: an event will be assumed not to have occurred in partic-
ipants without a reported outcome. For other outcomes, we will
analyse only the available data. Any imputation undertaken will
be subjected to sensitivity analysis.
Assessment of heterogeneity
Clinical and methodological heterogeneity
To evaluate the presence of clinical and methodological hetero-
geneity, we will generate descriptive statistics for trial and study
population characteristics across all eligible trials that compare
each pair of interventions. We will assess the presence of clinical
and methodological heterogeneity within each pairwise compari-
son by comparing these characteristics. Additionally, we will con-
sider whether there is sufficient similarity of the studied interven-
tions and characteristics of the couples across all included studies
for the network meta-analysis (i.e. the assumption of transitivity
in network meta-analyses). We will explore the distribution of po-
tential effect modifiers across the different pairwise interventions,
i.e. female age, duration of subfertility, primary/secondary subfer-
tility and if the women are treatment naive. In this study we expect
the transitivity assumption will hold assuming the following.
1. The common intervention used to compare with different
interventions indirectly is similar when it appears in different
RCTs (e.g. IUI is used in a similar way in an RCT comparing
IUI with expectant management as in an RCT comparing IUI
with IVF).
2. All pairwise comparisons do not differ with respect to the
distribution of effect modifiers (e.g. the design and study
characteristics of an RCT comparing IUI versus expectant
management are similar to an RCT comparing IUI versus IVF).
Statistical heterogeneity and inconsistency
Within each pairwise comparison we will assess statistical hetero-
geneity by the measure of the I2. An I2 measurement greater than
50% will be taken to indicate substantial heterogeneity (Higgins
2011).
Another key assumption for performing a network meta-analy-
sis is the consistency of the network, i.e. the agreement between
the direct and indirect sources of evidence. We will assess the
agreement between the various sources of evidence in the net-
work through two approaches: loop consistency and the design-
by-treatment method for the whole network. Loop inconsistency
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should be considered if the included studies have different treat-
ment comparisons, study populations or contexts (i.e. settings,
study periods) which could be substantially different in ways that
might affect the effect size of the comparison. Wewill furthermore
assess the assumption of consistency for the whole network using
the design-by-treatment method (Higgins 2012). This approach
allows for a global statistical test for the presence of inconsistency
of the whole network.
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publica-
tion bias and other reporting biases, we will aim to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert for duplication of data. If there are ten
or more studies in an analysis, we will use a comparison-adjusted
funnel plot to explore the possibility of small study effects (a ten-
dency for estimates of the intervention effect to be more beneficial
in smaller studies) (Chaimani 2013).
Data synthesis
We will compare interventions using ORs with their respective
95% confidence intervals. Whenmore than two studies compared
the same treatments, a random-effects summary OR will be cal-
culated.
We will conduct a network meta-analysis based on all investigated
comparisons between treatments and the indirect analysis can be
performed utilising all the possible pathways provided by the net-
work. An indirect estimate of A versus B can be calculated by
comparing direct comparisons of A versus C with trials of B ver-
sus C. In this way the OR for comparing A and B can be calcu-
lated using the following principle: ln(ORAvsB) = ln(ORAvsC)−
ln(ORBvsC). The direct and indirect evidence will be combined
for each comparison using the abovementioned analysis for direct
and indirect comparisons. We will use STATA for the analyses.
Subgroup analysis and investigation of heterogeneity
We will assess subgroup differences by interaction tests. We will
report the results of subgroup analysis quoting the Chi2 statistic
and P value, and the interaction test I2 value. If we detect substan-
tial heterogeneity, we will explore possible explanations in sub-
group analyses (e.g. differing populations) and/or sensitivity anal-
yses (e.g. differing risk of bias). We will take any statistical het-
erogeneity into account when interpreting the results, especially if
there is any variation in the direction of effect.
Where data are available from at least two studies, we will conduct
subgroup analyses for the primary outcomes only to determine the
separate evidence within the following subgroups.
1. Younger women (=< 38 years) versus older women (> 38
years).
2. Treatment naïve couples versus couples who have received
prior treatment.
3. Short duration of subfertility (<= 2 years) versus long
duration of subfertility (> 2 years).
4. IVF with single embryo transfer versus IVF with dual or
more embryo transfer.
5. IUI with follicle stimulating hormone (FSH) versus IUI
with clomiphene citrate (CC).
Sensitivity analysis
We will conduct sensitivity analyses for the primary outcomes
to determine whether the conclusions are robust to arbitrary de-
cisions made regarding the eligibility and analysis. These analy-
ses will include consideration of whether the review conclusions
would have differed if:
1. eligibility had been restricted to studies with no domains at
high risk of bias;
2. alternative imputation strategies had been implemented;
3. eligibility had varied by publication type (abstract versus
full text); or
4. we had included only studies with the outcome live birth.
Overall quality of the body of evidence: ’Summary of
findings’ table
We will prepare a ’Summary of findings’ (SoF) table using
GRADEpro software. We will follow the approach suggested by
the GRADE Working Group (Puhan 2014). The SoF table will
evaluate the overall quality of the body of evidence for the main
review outcomes (live birth or ongoing pregnancy, multiple preg-
nancy, clinical pregnancy, moderate/severe ovarian hyperstimula-
tion syndrome) for each comparison. We will provide estimates of
the direct and indirect evidence and of the network meta-analysis.
We will assess the quality of the evidence using GRADE criteria:
risk of bias, consistency of effect, imprecision, indirectness and
publication bias. Judgements about evidence quality (high, mod-
erate, low or very low) will be made by two review authors working
independently, with disagreements resolved by discussion. Judge-
ments will be justified, documented, and incorporated into the
reporting of results for each outcome.
A C K N OW L E D G E M E N T S
None.
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A P P E N D I C E S
Appendix 1. Cochrane Gynaecology and Fertility Group (CGF) search strategy
From inception to present
Procite platform
Keywords CONTAINS “unexplained and endometriosis related infertility” or “unexplained infertility” or “unexplained subfertility” or
“idiopathic infertility ”or “idiopathic male infertility” or “idiopathic subfertility” or Title CONTAINS “unexplained and endometriosis
related infertility” or “unexplained infertility” or “unexplained subfertility” or “idiopathic infertility” or “idiopathic male infertility” or
“idiopathic subfertility”
Appendix 2. Cochrane Central Register of Studies Online (CRSO) search strategy
From inception to present
CRSO web platform
#1 MESH DESCRIPTOR Infertility EXPLODE ALL TREES
#2 unexplained:TI,AB,KY
#3 idiopathic:TI,AB,KY
#4 #2 OR #3
#5 #1 AND #4
#6 (unexplain* adj5 infertil*):TI,AB,KY
#7 (unexplain* adj5 subfertil*):TI,AB,KY
#8 (idiopathic adj5 subfertil*):TI,AB,KY
#9 (idiopathic adj5 infertil*):TI,AB,KY
#10 (unknown adj5 subfertil*):TI,AB,KY
#11 (unknown adj5 infertil*):TI,AB,KY
#12 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11
Appendix 3. MEDLINE search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In Process & Other Non-Indexed Citations, Ovid MEDLINE (R) Daily, and
Ovid MEDLINE (R) 1946-Present
1 exp Infertility/ and unexplained.tw.
2 exp Infertility/ and idiopathic.tw.
3 (unexplain* adj5 infertil*).tw.
4 (unexplain* adj5 subfertil*).tw.
5 (idiopathic adj5 subfertil*).tw.
6 (idiopathic adj5 infertil*).tw.
7 (unknown adj3 infertil*).tw.
8 (unknown adj3 subfertil*).tw.
9 (unexplained adj3 steril*).tw.
10 (idiopathic adj3 steril*).tw.
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11 (unknown adj3 steril*).tw.
12 or/1-11
13 exp Clomiphene/
14 clomifene.tw.
15 clomiphene.tw.
16 Serophene.tw.
17 clomid.tw.
18 selective estrogen receptor modulators/ or exp raloxifene hydrochloride/ or exp tamoxifen/
19 selective estrogen receptor modulator*.tw.
20 (SERMs or SERM).tw.
21 (raloxifene or tamoxifen).tw.
22 or/13-21
23 Aromatase Inhibitors/
24 Aromatase inhibitor*.tw.
25 letrozole.tw.
26 (femara or anastrozole).tw.
27 (anti-?estrogen* or anti?estrogen*).tw.
28 or/23-27
29 exp follicle stimulating hormone/ or exp follicle stimulating hormone, beta subunit/ or exp glycoprotein hormones, alpha subunit/
or exp menotropins/ or exp urofollitropin/
30 Follicle Stimulating Hormone*.tw.
31 (FSH or rFSH or recFSH).tw.
32 (uFSH or rhFSH).tw.
33 (hpFSH or pFSH).tw.
34 (follitropin or Gonal F).tw.
35 (menotropin* or menopur).tw.
36 corifollitropin.tw.
37 (urofollitropin or pergonal or bravelle* or follitrin).tw.
38 Follistim*.tw.
39 (Puregon or humegon or menogon).tw.
40 human menopausal gonadotrop?in.tw.
41 growth hormone.tw.
42 HMG.tw.
43 gonadotrop?in*.tw.
44 or/29-43
45 expectant management.tw.
46 watchful waiting.tw.
47 (watch and wait).tw.
48 Coitus/
49 coitus.tw.
50 intercourse.tw.
51 sex*.tw.
52 or/45-51
53 exp Insemination, Artificial/
54 intrauterine insemination*.tw.
55 artificial insemination*.tw.
56 superovulat*.tw.
57 IUI.tw.
58 or/53-56
59 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/
60 embryo transfer*.tw.
61 vitro fertili?ation.tw.
62 ivf.tw.
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63 icsi.tw.
64 intracytoplasmic sperm injection*.tw.
65 (blastocyst adj2 transfer*).tw.
66 exp reproductive techniques, assisted/ or exp insemination, artificial/ or exp ovulation induction/
67 assisted reproduct*.tw.
68 ovulation induc*.tw.
69 (ovar* adj2 stimulat*).tw.
70 ovarian hyperstimulation.tw.
71 COH.tw.
72 (ovar* adj2 induc*).tw.
73 (modified adj3 cycle*).tw.
74 (natural adj3 cycle*).tw.
75 MNC IVF.tw.
76 (NCIVF or NC-IVF).tw.
77 unstimulated ivf.tw.
78 (unstimulated adj2 in vitro fertili?ation).tw.
79 (artificial adj3 cycle$).tw.
80 or/59-79
81 22 or 28 or 44 or 52 or 58 or 80
82 12 and 81
83 randomised controlled trial.pt.
84 controlled clinical trial.pt.
85 randomized.ab.
86 randomised.ab.
87 placebo.tw.
88 clinical trials as topic.sh.
89 randomly.ab.
90 trial.ti.
91 (crossover or cross-over or cross over).tw.
92 or/83-91
93 exp animals/ not humans.sh.
94 92 not 93
95 82 and 94
Appendix 4. Embase search strategy
From 1980 to present
Ovid platform
1 (exp infertility/ or exp infertility therapy/) and unexplained.tw.
2 (exp infertility/ or exp infertility therapy/) and idiopathic.tw.
3 (unexplain* adj5 infertil*).tw.
4 (unexplain* adj5 subfertil*).tw.
5 (idiopathic adj5 subfertil*).tw.
6 (idiopathic adj5 infertil*).tw.
7 (unknown adj3 infertil*).tw.
8 (unknown adj3 subfertil*).tw.
9 (unexplained adj3 steril*).tw.
10 (idiopathic adj3 steril*).tw.
11 (unknown adj3 steril*).tw.
12 or/1-11
13 exp clomifene/
14 clomifene.tw.
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15 clomiphene.tw.
16 Serophene.tw.
17 clomid.tw.
18 exp selective estrogen receptor modulator/
19 exp raloxifene/
20 exp tamoxifen citrate/ or exp tamoxifen/
21 selective estrogen receptor modulator*.tw.
22 (SERMs or SERM).tw.
23 (raloxifene or tamoxifen).tw.
24 or/13-23
25 exp aromatase inhibitor/
26 Aromatase inhibitor*.tw.
27 letrozole.tw.
28 (femara or anastrozole).tw.
29 (anti-?estrogen* or anti?estrogen*).tw.
30 or/25-29
31 exp follitropin/
32 exp human menopausal gonadotropin/
33 exp urofollitropin/
34 Follicle Stimulating Hormone*.tw.
35 (FSH or rFSH or recFSH).tw.
36 (uFSH or rhFSH).tw.
37 (hpFSH or pFSH).tw.
38 (follitropin or Gonal F).tw.
39 (menotropin* or menopur).tw.
40 corifollitropin.tw.
41 (urofollitropin or pergonal or bravelle* or follitrin).tw.
42 Follistim*.tw.
43 (Puregon or humegon or menogon).tw.
44 human menopausal gonadotrop?in.tw.
45 growth hormone.tw.
46 HMG.tw.
47 gonadotrop?in*.tw.
48 or/31-47
49 expectant management.tw.
50 watchful waiting.tw.
51 (watch and wait).tw.
52 exp coitus/
53 coitus.tw.
54 intercourse.tw.
55 sex*.tw.
56 or/49-55
57 exp artificial insemination/
58 intrauterine insemination*.tw.
59 artificial insemination*.tw.
60 superovulat*.tw.
61 IUI.tw.
62 or/49-61
63 exp fertilization in vitro/
64 exp embryo transfer/
65 exp intracytoplasmic sperm injection/
66 embryo transfer*.tw.
67 vitro fertili?ation.tw.
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68 ivf.tw.
69 icsi.tw.
70 intracytoplasmic sperm injection*.tw.
71 (blastocyst adj2 transfer*).tw.
72 exp infertility therapy/
73 exp artificial insemination/
74 exp ovulation induction/
75 assisted reproduct*.tw.
76 ovulation induc*.tw.
77 (ovar* adj2 stimulat*).tw.
78 ovarian hyperstimulation.tw.
79 COH.tw.
80 (ovar* adj2 induc*).tw.
81 (modified adj3 cycle*).tw.
82 (natural adj3 cycle*).tw.
83 MNC IVF.tw.
84 (NCIVF or NC-IVF).tw.
85 unstimulated ivf.tw.
86 (unstimulated adj2 in vitro fertili?ation).tw.
87 (artificial adj3 cycle$).tw.
88 or/63-87
89 24 or 30 or 48 or 56 or 62 or 88
90 Clinical Trial/
91 Randomized Controlled Trial/
92 exp randomization/
93 Single Blind Procedure/
94 Double Blind Procedure/
95 Crossover Procedure/
96 Placebo/
97 Randomi?ed controlled trial$.tw.
98 Rct.tw.
99 random allocation.tw.
100 randomly.tw.
101 randomly allocated.tw.
102 allocated randomly.tw.
103 (allocated adj2 random).tw.
104 Single blind$.tw.
105 Double blind$.tw.
106 ((treble or triple) adj blind$).tw.
107 placebo$.tw.
108 prospective study/
109 or/90-108
110 case study/
111 case report.tw.
112 abstract report/ or letter/
113 or/110-112
114 109 not 113
115 (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
116 114 not 115
117 12 and 89 and 116
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Appendix 5. PsycINFO search strategy
From 1806 to present
Ovid platform
1 exp INFERTILITY/ and unexplained.tw.
2 exp INFERTILITY/ and idiopathic.tw.
3 (unexplain* adj5 infertil*).tw.
4 (unexplain* adj5 subfertil*).tw.
5 (idiopathic adj5 infertil*).tw.
6 (unknown adj3 infertil*).tw.
7 (unexplained adj3 steril*).tw.
8 (idiopathic adj3 steril*).tw.
9 (unknown adj3 steril*).tw.
10 or/1-9
11 random*.ti,ab,hw,id.
12 trial*.ti,ab,hw,id.
13 controlled stud*.ti,ab,hw,id.
14 placebo*.ti,ab,hw,id.
15 ((singl* or doubl* or trebl* or tripl*) and (blind* or mask*)).ti,ab,hw,id.
16 (cross over or crossover or factorial* or latin square).ti,ab,hw,id.
17 (assign* or allocat* or volunteer*).ti,ab,hw,id.
18 treatment effectiveness evaluation/
19 mental health program evaluation/
20 exp experimental design/
21 or/11-20
22 10 and 21
Appendix 6. CINAHL search strategy
From 1982 to present
Ebsco platform
# Query
S23 S10 AND S22
S22 S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
S21 TX allocat* random*
S20 (MH “Quantitative Studies”)
S19 (MH “Placebos”)
S18 TX placebo*
S17 TX random* allocat*
S16 (MH “Random Assignment”)
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(Continued)
S15 TX randomi* control* trial*
S14 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S13 TX clinic* n1 trial*
S12 PT Clinical trial
S11 (MH “Clinical Trials+”)
S10 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S9 TX(idiopathic N3 steril*)
S8 TX(unknown N3 subfertil*)
S7 TX(unknown N3 infertil*)
S6 TX(idiopathic N5 infertil*)
S5 TX(idiopathic N5 subfertil*)
S4 TX(unexplain* N5 subfertil*)
S3 TX (unexplain* N5 infertil*)
S2 (MM “Infertility”) and TX idiopathic
S1 (MM “Infertility”) and TX unexplained
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